Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impact of MEM40 and IFNB on human DC activation markers

ABSTRACT: Impact of MEM40 and IFNB on human DC activation markers

PROVIDER: PRJNA925839 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23149206_1.fastq.gz	Fastqsanger.gz
	SRR23149206_2.fastq.gz	Fastqsanger.gz
	SRR23149207_1.fastq.gz	Fastqsanger.gz
	SRR23149207_2.fastq.gz	Fastqsanger.gz
	SRR23149208_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Impact of MEM40 and IFNB on human DC activation markers

Project description:To determine the impact of MEM40 and IFNB on normal human donor monocyte-derived DCs (Mo-DCs) phenotype, we used an experimental design where human A549 lung cancer cells were first infected with Ad-Null or adenoviruses expressing human IFNB, MEM40 or MEM40 + IFNB, followed by removal of virus-containing supernatant and co-culture with Mo-DCs. We used the above design followed by sorting of MHC-II+ CD11c+ cells for bulk RNA-sequencing.

2023-02-13 | GSE223342 | GEO

Transcriptome profiling of primary murine fibroblast response to IFNB with or without prior Drosha depletion

Project description:To assess the impact of Drosha on the response to IFNB

2017-06-28 | GSE96889 | GEO

Pharmacogenomics of IFNb therapy

Project description:This experiment set is used for the manuscript entitled: Pharmacogenomics of Interferon-b therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients. In this study we generated and analyzed pre- and post- IFNb treatment gene expression patterns of RRMS patients with the aim of identifying pre-existing and/or drug-induced signatures that will allow us to make predictions on the expected pharmacological effects of IFNb treatment. We show that the expression level of IFN response genes prior to treatment, determines the pharmacological differences between patients with MS at the molecular level. A group of 16 Dutch patients (10 females and 6 males) with clinically definite relapsing-remitting MS was recruited from the outpatient clinic of the MS Centre Amsterdam. Mean age at start of IFNb therapy is 40.6 +/- 7.7, mean EDSS is 2.3 +/- 1.3 (range 1-6). Blood samples were obtained just before treatment and 1 month after start of the therapy. Patients received Avonex, Betaferon, Rebif 22 or Rebif 44. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Before and 1 month after IFNb therapy Keywords: compound_treatment_design Complex

2008-04-01 | E-GEOD-10655 | biostudies-arrayexpress

Pharmacogenomics of IFNb therapy

2008-04-01 | GSE10655 | GEO

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [scRNAseq DC]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [scRNAseq DC]

| PRJNA813683 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ChIPseq DC]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ChIPseq DC]

| PRJNA813678 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq DC]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq DC]

| PRJNA813679 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ATACseq DC]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ATACseq DC]

| PRJNA813684 | ENA

Cytokines & Chemokines PCR Array on human DC

Project description:Stimulation of human DC with LPS, VSL#3, or a combination of both resulted in their maturation, evident from enhanced expression of activation markers on the cell-surface, as well as the induction of various chemokines and cytokines.

2014-10-23 | GSE62583 | GEO

Gene-profile comparison of wt and Ifnb–/– cerebellar granular neurons

Project description:Interferon-b (IFN-b) belongs to the type I interferon family of cytokines and via binding to its receptor, interferon-a/b-receptor (IFNAR), it exerts immunoregulatory effects such as anti-viral and anti-inflammatory properties, and clinical benefits for patients with the CNS disease multiple sclerosis. To compare differentially regulated genes in neurons of interferon-beta knock out mice (Ifnb–/–), we conducted a microarray analysis on cerebellar granular neurons (CGNs) from wt (Ifnb+/+) and Ifnb-/- mice with or without treatment with recombinant IFN-b.

2015-10-08 | GSE63815 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data